or Try an Advanced Search...

    Transplant Rejection Stocks List

    Symbol Grade Name % Change
    BMY B Bristol-Myers Squibb Company 1.63
    CDNA B CareDx, Inc. 0.73
    ALKS B Alkermes plc 0.59
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine

    Related ETFs - A few ETFs which own one or more of the above listed Transplant Rejection stocks.

    Symbol Grade Name Weight
    FTXH D First Trust Nasdaq Pharmaceuticals ETF 8.51
    JFWD C Jacob Funds Inc. Jacob Forward ETF 6.94
    ARKG F ARK Genomic Revolution Multi-Sector ETF 6.66
    RDIV B RevenueShares Ultra Dividend Fund 5.39
    PPH D Market Vectors Pharmaceutical ETF 5.02
    View all Transplant Rejection ETFs...
    Compare ETFs
    Compare FTXH to ARKG Compare FTXH to JFWD Compare FTXH to PPH

        Transplant Rejection Stocks Recent News

        Date Stock Title
        Oct 2 BMY STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
        Oct 2 ALKS Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years
        Oct 1 BMY PRME Stock Rises 11.8% on Collaboration With Bristol Myers
        Oct 1 BMY A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
        Oct 1 BMY BMS and Prime ink potential $3.5bn deal to develop T cell therapies
        Oct 1 BMY Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
        Oct 1 BMY 5 FDA decisions to watch in the fourth quarter
        Oct 1 BMY Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
        Sep 30 BMY Bristol Myers gets $6.4B Celgene CVR case dismissed: report
        Sep 30 BMY Sector Update: Health Care Stocks Advance Late Afternoon
        Sep 30 BMY US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals
        Sep 30 BMY Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
        Sep 30 BMY Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
        Sep 30 BMY Bristol, Prime Medicine in deal to develop T-cell therapies
        Sep 30 BMY Company News for Sep 30, 2024
        Sep 30 BMY Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
        Sep 30 BMY Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
        Sep 30 BMY Prime to narrow gene editing research as it strikes deal with Bristol Myers
        Sep 29 CDNA CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
        Sep 28 BMY 3 Surprisingly Underrated Stocks to Buy Right Now
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine
        Transplant Rejection

        Transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Transplant rejection can be lessened by determining the molecular similitude between donor and recipient and by use of immunosuppressant drugs after transplant.

        More about Transplant Rejection
        Browse All Tags